Advertisement

Association between multiple gene promoter hypermethylation and the risk of gastric cancer: A systematic review and meta-analysis

  • JianRu Wen
    Affiliations
    College of Medicine, Southwest Jiaotong University, Chengdu 610031, China

    Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China
    Search for articles by this author
  • SiXiu Deng
    Affiliations
    Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China

    College of Medicine, Southwest Medical University, Luzhou 646000, China
    Search for articles by this author
  • YuHua Bi
    Affiliations
    College of Medicine, Southwest Jiaotong University, Chengdu 610031, China

    Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China
    Search for articles by this author
  • LiJuan Qiao
    Affiliations
    Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China
    Search for articles by this author
  • Hui Xu
    Correspondence
    Corresponding author at: College of Medicine, Southwest Jiaotong University, Chengdu 610031, China.
    Affiliations
    College of Medicine, Southwest Jiaotong University, Chengdu 610031, China

    Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu 610083, China
    Search for articles by this author
Published:April 18, 2022DOI:https://doi.org/10.1016/j.dld.2022.03.009

      Abstract

      Background

      Several studies have demonstrated an association between multiple gene hypermethylation and gastric cancer. However, the intrinsic mechanisms remain elusive and highly debatable. To this end, our study aims to investigate the correlation between the methylation status of multiple gene promoters and gastric cancer.

      Methods

      PubMed, EMBASE, CNKI, WanFang, Cqvip, and Cochrane Library were queried from inception to May 2021, and the relationship between the methylation status of the CpG islands and gastric cancer risk was systematically assessed under the inclusion and exclusion criteria. The incidence of DNA methylation between tumor and non-tumor tissues was compared, and the clinicopathological significance of DNA methylation in gastric carcinoma was further evaluated. The odds ratio (OR) was estimated with a 95% confidence interval (CI), and forest plots were generated using the fixed-effects or random-effects model.

      Results

      In total, 201 studies were enrolled, and a higher frequency of CpG islands methylation was identified in gastric cancer tissues than in non-neoplastic tissues. This suggests that aberrant polygene methylation might be associated with the initial onset and progression of gastric cancer.

      Conclusion

      This study sheds light on the significance of polygene methylation status in gastric cancer. The DNA methylation of these genes may serve as underlying epigenetic biomarkers, providing a promising molecular diagnostic approach for human gastric cancer clinical diagnosis. More large randomized trials are needed to confirm the findings.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Digestive and Liver Disease
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Smyth E.C.
        • Nilsson M.
        • Grabsch H.I.
        • van Grieken N.C.
        • Lordick F.
        Gastric cancer.
        Lancet. 2020; 396: 635-648
        • Ajani J.A.
        • Lee J.
        • Sano T.
        • Janjigian Y.Y.
        • Fan D.
        • Song S.
        Gastric adenocarcinoma.
        Nat Rev Dis Prim. 2017; 3: 17036
        • Karimi P.
        • Islami F.
        • Anandasabapathy S.
        • Freedman N.D.
        • Kamangar F.
        Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention.
        Cancer Epidemiol Biomark Prev. 2014; 23: 700-713
        • Tan P.
        • Yeoh K.G.
        Genetics and molecular pathogenesis of gastric adenocarcinoma.
        Gastroenterology. 2015; 149: 1153-1162.e3
        • Fang X.Y.
        • Pan H.F.
        • Leng R.X.
        • Ye D.Q.
        Long noncoding RNAs: novel insights into gastric cancer.
        Cancer Lett. 2015; 356: 357-366
        • Canale M.
        • Casadei-Gardini A.
        • Ulivi P.
        • et al.
        Epigenetic Mechanisms in gastric cancer: potential new therapeutic opportunities.
        Int J Mol Sci. 2020; 21: 5500
        • Tie J.
        • Zhang X.
        • Fan D.
        Epigenetic roles in the malignant transformation of gastric mucosal cells. Cellular and molecular life sciences.
        CMLS. 2016; 73: 4599-4610
        • Bure I.V.
        • Nemtsova M.V.
        Methylation and noncoding RNAs in gastric cancer: everything is connected.
        Int J Mol Sci. 2021; 22: 5683
        • Ahsan S.
        • Raabe E.H.
        • Haffner M.C.
        • et al.
        Increased 5-hydroxymethylcytosine and decreased 5-methylcytosine are indicators of global epigenetic dysregulation in diffuse intrinsic pontine glioma.
        Acta Neuropathol Commun. 2014; 2: 59
        • Pfeifer G.P.
        Defining driver DNA methylation changes in human cancer.
        Int J Mol Sci. 2018; 19: 1166
        • Padmanabhan N.
        • Ushijima T.
        • Tan P.
        How to stomach an epigenetic insult: the gastric cancer epigenome.
        Nat Rev Gastroenterol Hepatol. 2017; 14: 467-478
        • Julian P.T.
        • Higgins J.T.
        • Chandler J.
        • Cumpston M.
        • Li T.
        • Page M.J.
        • Welch V.A.
        Cochrane handbook for systematic reviews of interventions.
        2nd ed. John Wiley & Sons, 2019
        • Dinis-Ribeiro M.
        • Areia M.
        • de Vries A.C.
        • et al.
        Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European society of gastrointestinal endoscopy (ESGE), European helicobacter study group (EHSG), European society of pathology (ESP), and the sociedade portuguesa de endoscopia digestiva (SPED).
        Endoscopy. 2012; 44: 74-94
        • Shim Y.H.
        • Kang G.H.
        • Ro J.Y.
        Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas.
        Lab Invest. 2000; 80: 689-695
        • He X.S.
        • Su Q.
        • Chen Z.C.
        • et al.
        Expression, deletion [was deleton] and mutation of p16 gene in human gastric cancer.
        World J Gastroenterol. 2001; 7: 515-521
        • Bae H.J.
        • Kang S.K.
        • Kwon W.S.
        • et al.
        p16 methylation is a potential predictive marker for abemaciclib sensitivity in gastric cancer.
        Biochem Pharmacol. 2021; 183114320
        • Tamura G.
        • Yin J.
        • Wang S.
        • et al.
        E-cadherin gene promoter hypermethylation in primary human gastric carcinomas.
        J Natl Cancer Inst. 2000; 92: 569-573
        • Tamura G.
        Alterations of tumor suppressor and tumor-related genes in the development and progression of gastric cancer.
        World J Gastroenterol. 2006; 12: 192-198
        • Wani M.
        • Afroze D.
        • Makhdoomi M.
        • et al.
        Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley.
        Asian Pac J Cancer Prev APJCP. 2012; 13: 4177-4181
        • Michailidi C.
        • Theocharis S.
        • Tsourouflis G.
        • et al.
        Expression and promoter methylation status of hMLH1, MGMT, APC, and CDH1 genes in patients with colon adenocarcinoma.
        Exp Biol Med. 2015; 240 (Maywood, NJ): 1599-1605
        • Kuester D.
        • El-Rifai W.
        • Peng D.
        • et al.
        Silencing of MGMT expression by promoter hypermethylation in the metaplasia-dysplasia-carcinoma sequence of Barrett's esophagus.
        Cancer Lett. 2009; 275: 117-126
        • Hegi M.E.
        • Ichimura K.
        MGMT testing always worth an emotion.
        Neuro Oncol. 2021; 23: 1417-1418
        • Ito K.
        • Lim A.C.
        • Salto-Tellez M.
        • et al.
        RUNX3 attenuates beta-catenin/T cell factors in intestinal tumorigenesis.
        Cancer Cell. 2008; 14: 226-237
        • Peng Z.
        • Wei D.
        • Wang L.
        • et al.
        RUNX3 inhibits the expression of vascular endothelial growth factor and reduces the angiogenesis, growth, and metastasis of human gastric cancer.
        Clin Cancer Res. 2006; 12: 6386-6394
        • Dammann R.
        • Li C.
        • Yoon J.H.
        • Chin P.L.
        • Bates S.
        • Pfeifer G.P.
        Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3.
        Nat Genet. 2000; 25: 315-319
        • Nakamura J.
        • Tanaka T.
        • Kitajima Y.
        • Noshiro H.
        • Miyazaki K.
        Methylation- mediated gene silencing as biomarkers of gastric cancer: a review.
        World J Gastroenterol. 2014; 20: 11991-12006
        • Ebrahimi V.
        • Soleimanian A.
        • Ebrahimi T.
        • et al.
        Epigenetic modifications in gastric cancer: focus on DNA methylation.
        Gene. 2020; 742144577
        • Dammann R.
        • Schagdarsurengin U.
        • Strunnikova M.
        • et al.
        Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis.
        Histol Histopathol. 2003; 18: 665-677
        • Tur M.K.
        • Daramola A.K.
        • Gattenlöhner S.
        • Herling M.
        • Chetty S.
        • Barth S.
        Restoration of DAP kinase tumor suppressor function: a therapeutic strategy to selectively induce apoptosis in cancer cells using immunokinase fusion proteins.
        Biomedicines. 2017; 5: 59
        • Li Y.
        • Zhu M.
        • Zhang X.
        • Cheng D.
        • Ma X.
        Clinical significance of DAPK promoter hypermethylation in lung cancer: a meta-analysis.
        Drug Des Dev Ther. 2015; 9: 1785-1796
        • Yuan W.
        • Chen J.
        • Shu Y.
        • et al.
        Correlation of DAPK1 methylation and the risk of gastrointestinal cancer: a systematic review and meta-analysis.
        PLoS One. 2017; 12e0184959
        • Li Y.
        • Shi Y.
        • Wang X.
        • Yu X.
        • Wu C.
        • Ding S.
        Silencing of CHFR sensitizes gastric carcinoma to PARP inhibitor treatment.
        Transl Oncol. 2020; 13: 113-121
        • Scolnick D.M.
        • Halazonetis T.D.
        CHFR defines a mitotic stress checkpoint that delays entry into metaphase.
        Nature. 2000; 406: 430-435
        • Yang S.
        • He F.
        • Dai M.
        • Pan J.
        • Wang J.
        • Ye B.
        CHFR promotes the migration of human gastric cancer cells by inducing epithelial-to-mesenchymal transition in a HDAC1-dependent manner.
        Onco Targets Ther. 2019; 12: 1075-1084
        • Grady W.M.
        Epigenetic alterations in the gastrointestinal tract: current and emerging use for biomarkers of cancer.
        Adv. Cancer Res. 2021; 151: 425-468
        • Palanca-Ballester C.
        • Rodriguez-Casanova A.
        • Torres S.
        • et al.
        Cancer epigenetic biomarkers in liquid biopsy for high incidence malignancies.
        Cancers (Basel). 2021; 13 (Basel): 3016
        • Bates S.E.
        Epigenetic therapies for cancer.
        N Engl J Med. 2020; 383: 650-663
        • Topper M.J.
        • Vaz M.
        • Marrone K.A.
        • Brahmer J.R.
        • Baylin S.B.
        The emerging role of epigenetic therapeutics in immuno-oncology.
        Nat Rev Clin Oncol. 2020; 17: 75-90
        • Lu Y.
        • Chan Y.T.
        • Tan H.Y.
        • Li S.
        • Wang N.
        • Feng Y.
        Epigenetic regulation in human cancer: the potential role of epi-drug in cancer therapy.
        Mol Cancer. 2020; 19: 79